ERBB2 Comprehensive Profiling and Prognostication in Stage III Colon Cancer: Findings From PETACC8 and IDEA-France Cohorts.

doi:10.1053/j.gastro.2024.10.046

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

ERBB2 Comprehensive Profiling and Prognostication in Stage III Colon Cancer: Findings From PETACC8 and IDEA-France Cohorts.

Gastroenterology - 1 Apr 2025

Pilati Camilla, Soulabaille Audrey, Gallois Claire, Blons Hélène, Cayre Anne, Sroussi Marine, Le Corre Delphine, Mouillet-Richard Sophie, Mulot Claire, Le Malicot Karine, De Reynies Aurélien, Bachet Jean-Baptiste, Borg Christophe, Di Fiore Frédéric, Guimbaud Rosine, Bennouna Jaafar, André Thierry, Taieb Julien, Penault-Llorca Frédérique, Laurent-Puig Pierre

Abstract excerpt

BACKGROUND & AIMS: ERBB2 pathway activation, through amplification or activating mutations, represents a new target for colon cancer (CC) treatment. Molecular methods were compared with the gold standard for assessing ERBB2 status, and the prognostic value of ERBB2 amplification, mutations, and expression was determined using data from 2 phase 3 trials involving nearly 3000 patients with stage III CC. METHODS: In...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials, Phase III as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colonic Neoplasms

Share to Erb-b2 Receptor Tyrosine Kinases

Share to France

Share to Gene Amplification

Share to In Situ Hybridization, Fluorescence

Share to Neoplasm Staging

Share to Sequence Analysis, RNA

Source

Open in PubMed

Identifiers

PMID: 39612956
DOI: 10.1053/j.gastro.2024.10.046

Genes

ERBB2
TTR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ERBB2 Comprehensive Profiling and Prognostication in Stage III Colon Cancer: Findings From PETACC8 and IDEA-France Cohorts.PMID 39612956Read ↗

Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.Semantic proximity Read ↗

Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer.Semantic proximity Read ↗

Molecular characterization of ERBB2-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive cases.Semantic proximity Read ↗

Genomic landscape and clinical characteristics of ERBB2/HER2-mutated colorectal cancers.Semantic proximity Read ↗

HER2 in Metastatic Colorectal Cancer: Pathology, Somatic Alterations, and Perspectives for Novel Therapeutic SchemesSemantic proximity Read ↗

HER2 in Colorectal Carcinoma: Are We There yet?Semantic proximity Read ↗

Molecular Landscape of ERBB2 Alterations in 14,956 Solid Tumors.Semantic proximity Read ↗

HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials.Semantic proximity Read ↗

Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value.Semantic proximity Read ↗

ctDNA Analysis in ERBB2 -Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway TrialSemantic proximity Read ↗

Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification StatusSemantic proximity Read ↗

ERBB2 emerges as a new target for colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.